Obesity surgery in the time of Ozempic: They are not two competing treatments, but rather complementary ones'

The emergence of innovative anti-obesity drugs, like GLP-1 receptor agonists, has drastically altered obesity management, decreasing bariatric surgery cases while increasing treatment options.

Prescription rates for GLP-1 receptor agonists surged by 123% from 2022 to 2023, while the number of bariatric surgeries fell by 25%, indicating a shift in obesity treatment.

Experts assert that both medication and surgery are essential in obesity management, leading to a critical review of strategies for treating this complex disease.

Despite the proliferation of new anti-obesity medications, bariatric surgery remains the most effective long-term treatment, raising questions about future treatment approaches.

Read at english.elpais.com